Business
MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline
VICTORIA, British Columbia--(BUSINESS WIRE)-- MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and
About this update from Mindwalk Holdings Corp.
[{"type":"text","content":" VICTORIA, British Columbia--(BUSINESS WIRE)--\nMindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologics discovery and development, today announced financial results for the second quarter of fiscal 2026 and provided updates on its AI driven asset pipeline and strategic initiatives. MindWalk operates a proprietary BioNative AI platform built on patented HYFT® patterns—evolution shaped subsequence codes that link sequence, structure and function. These patterns underpin LensAI™, a software platform that harmonizes and analyzes diverse biological data to deliver actionable insights.\n\nFinancial Highlights (Quarter Ended October 31, 2025)\n\n\nRevenue: $4.1 million, up 54% year-over-year and 30% sequentially, driven by improved project revenue and better utilization across both project-based and platform-related revenue streams.\n\n\n\nGross margin: 65%, up from 51% in the prior year quarter. Gross profit increased significantly, by 94% year-over-year to $2.7 million, as fixed cost leverage and higher margin projects improved profitability.\n\n\n\nOperating loss, excluding amortization and nonrecurring items, improved notably to $2.8 million from $4.1 million a year ago.\n\n\n\nAdjusted EBITDA: Loss improved to $2.4 million, versus $2.6 million in the prior year period.\n\n\n\nLiquidity: Cash and cash equivalents of $16.5 million at quarter end (including proceeds from the sale of the Company’s former Netherlands operations), providing flexibility to invest in platform expansion and inhouse pipeline programs.\n\n\nStrategic and Operational Highlights\n\nMajor portfolio progress\n\n\nGLP1 & longevity program – MindWalk advanced its AI designed GLP1 receptor agonist program, achieving receptor activation above semaglutide in in vitro assays. The Company also identified a companion pathway linked to aging biology and is developing a dual pathway regimen aimed at metabolic control and longevity.\n\n\n\nUniversal dengue vaccine initiative – Using its LensAI platform, which leverages HYFT patterns to analyze multi‑omic data, MindWalk pinpointed a highly conserved, discontinuous epitope shared across all four dengue virus serotypes. Preclinical planning is under way with completion anticipated early next quarter, and a collaborator has been selected to...